Search results
7 cze 2023 · Metastatic breast cancer patients with HER2 IHC 1+ or 2+/ISH negative results (on either the primary or metastatic sample) can be considered for treatment if they meet other clinical eligibility criteria.
25 lip 2016 · In summary, implementation of AC2013 guidelines resulted in more patients initially interpreted as equivocal, which led to increased additional testing to resolve equivocal FISH results, and more women with IHC 2+ breast cancer were found positive by FISH.
10 sty 2024 · Recommendations. Clinicians should recommend treatment according to menopausal status, pathological and biomarker features when quality results are available. In first-line, for hormone receptor (HR)–positive MBC, when a non-steroidal aromatase inhibitor and CDK 4/6 inhibitor combination is unavailable, use hormonal therapy alone.
17 kwi 2020 · FISH testing of the HER2 gene locus has a well-documented value for breast cancer patients. Personalized therapy can be used after assessing the HER2 gene using one of the FDA-approved methods IHC, CISH or FISH, compared.
29 sie 2016 · The HER2 FISH status of BCIRG-005/006/007 patients with breast cancers was re-evaluated according to current ASCO-CAP guidelines, which designates five different groups according to HER2 FISH ratio and average HER2 gene copy number per tumor cell: group 1 (in situ hybridization [ISH]–positive): HER2-to-chromosome 17 centromere ratio ≥ 2.0 ...
6 lis 2019 · Since the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines on HER2 testing was first released in 2007, it has been updated to provide clear instructions for HER2 testing and accurate determination of HER2 status in breast cancer.
2 lut 2019 · Abstract. Objectives. Human epidermal growth factor receptor 2 (HER2, ERBB2) is a valuable prognostic and predictive biomarker in breast cancer. Accurate assessment of HER2 status is essential in selecting the patients with invasive breast cancer who will likely response to HER2-targeted therapies.
